Table 2—

Median plasma concentrations (interquartile range) of ADMA and CRP grouped according to categorical baseline variables

ADMAP valueCRPP value
Sex
    Male (n = 74)0.57 (0.49–0.64)4.0 (2.0–6.8)
    Female (n = 51)0.58 (0.51–0.71)0.2804.0 (1.7–7.0)0.744
Smoking status
    Yes (n = 26)0.56 (0.52–0.63)5.0 (2.8–10.0)
    No (n = 89)0.57 (0.49–0.68)0.7693.8 (1.5–6.9)0.151
Hypertension
    Yes (n = 118)0.57 (0.50–0.67)4.0 (2.0–7.0)
    No (n = 7)0.55 (0.47–0.64)0.4591.8 (0.6–5.3)0.126
ACE/AT2*
    Yes (n = 109)0.57 (0.50–0.67)4.0 (2.0–7.0)
    No (n = 16)0.59 (0.47–0.64)0.5642.9 (1.4–5.3)0.268
Macrovascular disease
    Yes (n = 51)0.62 (0.54 to −0.73)5.0 (2.0–11.6)
    No (n = 74)0.55 (0.48–0.63)0.0043.5 (1.7–6.0)0.012
Hyperlipidaemia
    Yes (n = 71)0.55 (0.47–0.65)4.0 (2.0–6.1)
    No (n = 54)0.57 (0.53–0.67)0.2153.7 (1.0–8.4)0.744
Statin therapy
    Yes (n = 67)0.55 (0.47–0.65)4.0 (2.0–7.0)
    No (n = 58)0.58 (0.53–0.67)0.1103.8 (1.2–7.0)0.633
Insulin therapy
    Yes (n = 70)0.58 (0.50–0.68)4.1 (2.0–8.3)
    No (n = 55)0.56 (0.49–0.63)0.3843.5 (1.7–6.0)0.208
  • Mann Whitney U test was applied for comparisons between groups.

  • *

    * ACE/AT2, treatment with ACE inhibitors or angiotensin 2 receptor blockers.